Resveratrol prevented experimental pulmonary vascular remodeling via miR-638 regulating NR4A3/cyclin D1 pathway
Authors:
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Microvascular Research
- Vol. 130, 103988
Abstract
No abstract availableKeywords
Funding Information
- Suzhou Municipal Application Basic Research Project (SYS2019047)
- Jiangsu Province (QNRC2016745)
- Clinical Medicine Center of Suzhou (SZZX201502)
- Suzhou Key Laboratory for Respiratory Medicine (SZS201617)
This publication has 35 references indexed in Scilit:
- NR4A transcription factors limit CAR T cell function in solid tumoursNature, 2019
- Resveratrol Attenuates Allergic Asthma and Associated Inflammation in the Lungs Through Regulation of miRNA-34a That Targets FoxP3 in MiceFrontiers in Immunology, 2018
- Resveratrol protects mice against SEB‐induced acute lung injury and mortality by miR‐193a modulation that targets TGF‐β signallingJournal of Cellular and Molecular Medicine, 2018
- Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2Circulation, 2017
- MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial HypertensionCirculation Research, 2015
- microRNA and Pulmonary Hypertension2015
- Resveratrol prevents hypoxia-induced arginase II expression and proliferation of human pulmonary artery smooth muscle cells via Akt-dependent signalingAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2014
- miR-638 regulates gene expression networks associated with emphysematous lung destructionGenome Medicine, 2013
- Role for miR-204 in human pulmonary arterial hypertensionJournal of Experimental Medicine, 2011
- Resveratrol Prevents Monocrotaline-Induced Pulmonary Hypertension in RatsHypertension, 2009